Evaluation of Alone or Combined Colistin Therapy Success in Patients with Carbapenem-Resistant Acinetobacter Pneumonias

Basit Öğe Kaydı
dc.authoridDiken, Ozlem Ercen / 0000-0001-8388-9500
dc.authorwosidDiken, Ozlem Ercen / AAI-6625-2021
dc.authorwosidTumturk, Ayhanim / AAE-7427-2020
dc.contributor.authorDiken, Ozlem Ercen
dc.contributor.authorTumturk, Ayhanim
dc.contributor.authorArslan, Sertac
dc.date.accessioned2021-11-01T14:58:15Z
dc.date.available2021-11-01T14:58:15Z
dc.date.issued2015
dc.department[Belirlenecek]
dc.description.abstractAim Carbapenem-resistant gram negative bacteria represent an increasing problem worldwide for intensive care units. We aimed to detect the outcome of different treatment regimens and mortality rates of Acinetobacter infection in our clinic. Is combined colistin therapy superior or not? Material and Method: 23 cases diagnosed and treated in our unit with documented Acinetobacter infections between January 2013 and June 2014 were retrospectively evaluated in terms of treatments administered and mortality rates. Results: 19 of 23 patients were treated in ICU and 4 of 23 patients were treated in normal patient ward. Among 19 ICU patients, 2 patients in cefoperazone + sulbactam - susceptible groups and 3 patients with cefaperazone + sulbactam - resistant groups died with colistin monotherapy. Among patients receiving combined treatment, two patients were given amikacin + colistin combination and they both died. A single patient receiving colistin + rifampicin combination responded well. Of the 4 patients treated in the normal patient ward, 3 had carbapenem resistance, and of these, only 1 was susceptible to colistin. This patient received colistin + tigecycline combination and had good response. Discussion: The combined colistin treatment seems plausible in terms of reducing mortality in Acinetobacter infections of lung. We believe that in patients with carbapenem-resistant Acinetobacter infections, a consideration should be given to rifampicin or tigecycline combination with colistin.
dc.identifier.doi10.4328/JCAM.3654
dc.identifier.endpage637en_US
dc.identifier.issn1309-0720
dc.identifier.issn1309-2014
dc.identifier.startpage635en_US
dc.identifier.urihttps://doi.org/10.4328/JCAM.3654
dc.identifier.urihttps://hdl.handle.net/11491/6548
dc.identifier.volume6en_US
dc.identifier.wosWOS:000215598800015
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherDerman Medical Publ
dc.relation.ispartofJournal Of Clinical And Analytical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAcinetobactoren_US
dc.subjectColistinen_US
dc.subjectRifampicinen_US
dc.subjectTigecyclinen_US
dc.titleEvaluation of Alone or Combined Colistin Therapy Success in Patients with Carbapenem-Resistant Acinetobacter Pneumonias
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu